Shares of Cambrex Corp. were up more than 46 percent in trading after the company announced an agreement to be acquired by an affiliate of the Permira funds for $60 per share, totaling $2.4 billion.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Adaptive Biotechnologies announced plans to lease a new corporate headquarters, tripling the company’s footprint in Seattle.
Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.
Cambridge, Massachusetts-based LUCA Biologics launched and will focus on women’s health, beginning with urinary tract infections (UTI).
EVERSANA, a leading independent provider of global commercial services to the life science industry, announced the rapid expansion of the company’s Asia Pacific business with the addition of two new offices in Singapore and Mumbai.
GlaxoSmithKline transferred the company’s work on developing three potential vaccines against the Ebola and Marburg viruses.
Sosei inked a strategic multi-target partnership with Takeda to find, develop and commercialize small molecules and biologics that modulate G protein-coupled receptor (GPCR) targets.
Klick Inc. named to Fast Company’s first-ever list of Best Workplaces for Innovators, honoring businesses and organizations that demonstrate a deep commitment to encouraging innovation at all levels.
Pfizer announced that the company’s Phase III RESET clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the study’s primary and key secondary efficacy endpoints.